[ad_1] CNN — A congressional investigation found that the US Food and Drug Administration’s “atypical collaboration” to approve a high-priced Alzheimer’s drug was “rife with irregularities.” The report, released Thursday, was the result of an 18-month investigation by two House committees. It is sharply critical of Biogen, maker of the …
Read More »Aduhelm: House investigation says FDA approval process of Alzheimer’s drug was ‘rife with irregularities’
